Department Neurosurgery, University of Rochester Medical Center, Rochester.
Division of Neurosurgery, Bassett HealthCare, Cooperstown, New York, USA.
Curr Opin Crit Care. 2020 Apr;26(2):87-96. doi: 10.1097/MCC.0000000000000702.
Since the development of intravenous tissue plasminogen activator (tPA) for acute ischemic stroke (AIS), functional outcome has improved when treatment occurs within 4.5 h of stroke onset and treatment benefits are greater with earlier treatment. Endovascular revascularization also is better the sooner it is delivered.
The Get with the Guidelines Stroke registry found that less than one-third of treatment-eligible AIS patients receive intravenous tPA within 60 min of hospital arrival. Initiatives have tried to improve public education and awareness of stroke symptoms to decrease time to presentation. The mobile stroke unit (MSU) facilitates earlier computed tomography scans, delivery of tPA, proper triage and on-scene goal-directed care. MSUs reduce time from stroke alarm to treatment by 25-40 min and increase the rate of intravenous tPA use without an increase in hemorrhage risk. In addition, three-month favorable outcome is increased.
MSUs likely will evolve further and be used for other acute neurologic disorders, help triage patients for endovascular therapy, and be incorporated into systems of care in remote areas. Further studies are awaited to fully understand the overall medical and health-economic benefit of MSUs.
目的综述:自从静脉注射组织型纤溶酶原激活剂(tPA)用于急性缺血性脑卒中(AIS)以来,在发病后 4.5 小时内进行治疗时,功能预后得到改善,并且治疗越早,获益越大。血管内再通治疗也越快越好。
最新发现:Get with the Guidelines Stroke 注册研究发现,不到三分之一的适合治疗的 AIS 患者在入院后 60 分钟内接受静脉注射 tPA。各种举措已经尝试改善公众对中风症状的教育和认识,以减少就诊时间。移动卒中单元(MSU)可促进更快进行计算机断层扫描、tPA 给药、适当分诊和现场目标导向护理。MSU 将从卒中警报到治疗的时间缩短了 25-40 分钟,并增加了静脉注射 tPA 的使用率,而不会增加出血风险。此外,还提高了三个月时的有利转归。
总结:MSU 可能会进一步发展,并用于治疗其他急性神经系统疾病,帮助对血管内治疗的患者进行分诊,并被纳入偏远地区的护理系统中。需要进一步的研究来全面了解 MSU 的整体医疗和健康经济效益。